http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Jihong Cheng (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
XUYANG XIAO,DONGPING SHI,JIHONG XIA,ZHENGFU CHENG 성균관대학교(자연과학캠퍼스) 성균나노과학기술원 2013 NANO Vol.8 No.6
Atomic segregation in bimetallic clusters can influence the surface nucleation and also the structures of clusters. It is important to study the effect of atomic segregation on the structure. In this study, initial cooling temperatures were used to tune the atomic segregation ability. Molecular dynamics simulation with an embedded atom method was used to study the relationship between the structure and atomic segregation. It was found that the higher the initial cooling temperature, the more obvious the Ag atomic segregation. When the clusters cooled down from 800 K and 600 K, the clusters formed a mixed icosahedron due to the weak atomic segregation ability. When the initial cooling temperature is higher than 1200 K, all the Ag atoms segregated to the surface layer, the clusters formed a Pd–Ag-core–shell chemical ordering. For 1200 K initial temperature, the structure is decahedral. The clusters formed an fcc structure when the clusters cooled down from 2000 K, 1800 K, and 1500 K. When the clusters cooled down from 860 K and 900 K, not all the Ag atoms segregated to the surface layer, the clusters formed a core–shell chemical ordering with a mixed Pd–Ag core. But the structure of 860 K is twinned of icosahedron and decahedron and that of 900 K is decahedral. This means that the chemical orderings and structures were influenced by the atomic segregation.
-
-
Ting-Yan Shi,Sheng Yin,Jianqing Zhu,Ping Zhang,Jihong Liu,Libing Xiang,Yaping Zhu,Sufang Wu,Xiaojun Chen,Xipeng Wang,Yin-Cheng Teng,Tao Zhu,Aijun Yu,Yingli Zhang,Yanling Feng,He Huang,Wei Bao,Yanli Li 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.3
Background: In China, secondary cytoreductive surgery (SCR) has been widely used in ovarian cancer (OC) over the past two decades. Although Gynecologic Oncology Group-0213 trial did not show its overall survival benefit in first relapsed patients, the questions on patient selection and effect of subsequent targeting therapy are still open. The preliminary data from our pre-SOC1 phase II study showed that selected patients with second relapse who never received SCR at recurrence may still benefit from surgery. Moreover, poly(ADP-ribose) polymerase inhibitors (PARPi) maintenance now has been a standard care for platinum sensitive relapsed OC. To our knowledge, no published or ongoing trial is trying to answer the question if patient can benefit from a potentially complete resection combined with PARPi maintenance in OC patients with secondary recurrence. Methods: SOC-3 is a multi-center, open, randomized, controlled, phase II trial of SCR followed by chemotherapy and niraparib maintenance vs chemotherapy and niraparib maintenance in patients with platinum-sensitive second relapsed OC who never received SCR at recurrence. To guarantee surgical quality, if the sites had no experience of participating in any OC-related surgical trials, the number of recurrent lesions evaluated by central-reviewed positron emission tomography–computed tomography image shouldn't be more than 3. Eligible patients are randomly assigned in a 1:1 ratio to receive either SCR followed by 6 cycles of platinum-based chemotherapy and niraparib maintenance or 6 cycles of platinum-based chemotherapy and niraparib maintenance alone. Patients who undergo at least 4 cycles of chemotherapy and must be, in the opinion of the investigator, without disease progression, will be assigned niraparib maintenance. Major inclusion criteria are secondary relapsed OC with a platinum-free interval of no less than 6 months and a possibly complete resection. Major exclusion criteria are borderline tumors and non-epithelial ovarian malignancies, received debulking surgery at recurrence and impossible to complete resection. The sample size is 96 patients. Primary endpoint is 12-month non-progression rate. Trial Registration: ClinicalTrials.gov Identifier: NCT03983226
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
